Company Overview and News

89
Wanda and Tencent team up on ‘smart retail’ venture

2018-05-30 scmp
The partnership will aim to transform Wanda’s huge bricks-and-mortar presence into ‘smart’ shopping centres, and drive online traffic through Tencent’s platforms including WeChat
6808 SURRF BABA SURRY GRPN 0700 INTIF INTIY SNCHY

114
Walmart makes $16 billion bet on India

2018-05-09 nzherald.co.nz
Walmart will soon reach shoppers in India's massive consumer market directly, as it takes control of the online retailer Flipkart that's known for its ubiquitous delivery drivers on their motorcycles with oversized backpacks.
6808 SURRF BABA SURRY 0700 MSFT

81
Alibaba sees 2019 revenue growth above 60pc as quarterly profit hits 61.9b yuan

2018-05-04 scmp
China’s biggest e-commerce services provider is diversifying to combat slowing growth in its core business and fend off increased competition from rival Tencent
6808 SURRF BABA SURRY 1833 0700

0
Chinese consumers snap up 80,000 durians after Alibaba signs 3 billion yuan food deal with Thai government

2018-04-20 scmp
Chinese consumers ordered 80,000 durians the minute a new online promotion went live as part of a Chinese-Thai initiative to help sell the Southeast Asian country’s local products via the internet.
6808 SURRF SURRY

84
WeChat alliance allows shoppers to skip the queue at Walmart’s stores in China

2018-03-30 scmp
The world’s largest retailer has teamed up with internet giant Tencent to push mobile payments at its stores in China
6808 VIPS SURRF BABA SURRY 0700

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...